Last reviewed · How we verify
TRX518 with pembrolizumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TRX518 with pembrolizumab (TRX518 with pembrolizumab) — Leap Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TRX518 with pembrolizumab TARGET | TRX518 with pembrolizumab | Leap Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TRX518 with pembrolizumab CI watch — RSS
- TRX518 with pembrolizumab CI watch — Atom
- TRX518 with pembrolizumab CI watch — JSON
- TRX518 with pembrolizumab alone — RSS
Cite this brief
Drug Landscape (2026). TRX518 with pembrolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/trx518-with-pembrolizumab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab